Role of N-acetylcysteine and GSH redox system on total and active MMP-2 in intestinal myofibroblasts of Crohn's disease patients

Cecilia Romagnoli · Tommaso Marcucci · Lucia Picariello · Francesco Tonelli · Maria Teresa Vincenzini · Teresa Iantomasi

Abstract

Purpose Intestinal subepithelial myofibroblasts (ISEMFs) are the predominant source of matrix metalloproteinase-2 (MMP-2) in gut, and a decrease in glutathione/oxidized glutathione (GSH/GSSG) ratio, intracellular redox index, occurs in the ISEMFs of patients with Crohn's disease (CD). The aim of this study is to demonstrate a relationship between MMP-2 secretion and activation and changes of GSH/GSSG ratio in ISEMFs stimulated or not with tumor necrosis factor alpha (TNFα).

Methods ISEMFs were isolated from ill and healthy colon mucosa of patients with active CD. Buthionine sulfoximine, GSH synthesis inhibitor, and N-acetylcysteine (NAC), precursor of GSH synthesis, were used to modulate GSH/GSSG ratio. GSH and GSSG were measured by HPLC and MMP-2 by ELISA Kit.

Results In cells, stimulated or not with TNFα, a significant increase in MMP-2 secretion and activation, related to increased oxidative stress, due to low GSH/GSSG ratio, was detected. NAC treatment, increasing this ratio, reduced MMP-2 secretion and exhibited a direct effect on the secreted MMP-2 activity. In NAC-treated and TNFα-stimulated ISEMFs of CD patients' MMP-2 activity were restored to physiological value. The involvement of c-Jun N-terminal kinase pathway on redox regulation of MMP-2 secretion has been demonstrated.

Conclusion For the first time, in CD patient ISEMFs, a redox regulation of MMP-2 secretion and activation related to GSH/GSSG ratio and inflammatory state have been demonstrated. This study suggests that compounds able to maintain GSH/GSSG ratio to physiological values can be useful to restore normal MMP-2 levels reducing in CD patient intestine the dysfunction of epithelial barrier.

Keywords Total and active MMP-2 · Crohn's disease · GSH/GSSG ratio · N-acetylcysteine · Oxidative state

Introduction

Intestinal subepithelial myofibroblasts (ISEMFs) play an important role in different functions in the normal and pathological intestine being involved in tissue growth and repair, tumourigenesis, inflammation and fibrosis [1]. The intestinal location of ISEMFs, subjacent to the basement membrane juxtaposed to the basal surface of epithelial cells, is crucial for their involvement in the regulation of many functions of epithelial cells, including epithelial cell proliferation and differentiation, mucosal protection and wound healing [2]. ISEMFs contribute in the epithelium repair processes by synthesizing, in response to stimuli, growth factors, such as transforming growth factor, epidermal growth factor, proinflammatory cytokines, components of extracellular matrix (ECM) and enzymes responsible of ECM degradation [1, 3]. Matrix metalloproteinases (MMPs), a family of Zn2+-containing neutral proteinases, are secreted as inactive zymogens and are activated in the extracellular space in order to cleave their substrates. Given
that these enzymes are involved in the turnover and degradation of ECM, they play an important role in the normal tissue remodelling and in the modulation of matrix function [4]. Nevertheless, it has been demonstrated that MMPs act on substrates different from ECM proteins, regulate many physiological functions, such as cell proliferation, adhesion, migration, growth factor bioavailability, chemotaxis and signalling. The activity of MMPs is tightly controlled. In fact, their latent form is activated, owing to the break of the interaction between the residue cysteine and the zinc ion present in the catalytic site. MMPs are also regulated at transcriptional level by interleukins, growth factors and proinflammatory mediators, such as tumour necrosis factor alpha (TNFα) [5]. Activated MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMPs) which, by interacting with the catalytic site of MMPs, prevent their binding to substrates [5, 6]. MMPs play a crucial role also in pathological conditions such as atherosclerotic lesion development, inflammation, arthritis, tumour progression and diabetes [6, 7]. In an inflammatory state, such as in inflammatory bowel diseases (IBD), MMPs play the important role in controlling the function and migration of immune cells, chemokine activity, matrix deposition and degradation [8]. Nevertheless, a dysregulated expression of MMPs may contribute to intestinal tissue injury and inflammatory status in IBD [9], characterized by an imbalance between pro- and anti-inflammatory cytokines [10] and between synthesis and degradation of ECM components [11]. In fact, increased levels of MMPs found in inflamed tissue of IBD can be responsible of the ulceration and fistula formation [11]; on the contrary, an increased level of TIMP-1 protein is related to fibrotic structures restore [12]. In particular, in Crohn’s disease (CD), an increase in MMP production occurs, which induces mucosal degradation, local leukocyte accumulation into inflamed tissue and cytokine production [11].

MMP-9 and MMP-2 are the two known gelatinases that degrade collagen; MMP-9 is produced principally by macrophages and polymorphonuclear leukocytes, differently from MMP-2 produced mainly by fibroblasts and other connective tissue cells [13]. Both are up-regulated in inflamed intestine of IBD patients, and their increase is associated with disease severity and activity [13, 14]. In particular, high levels of MMP-2 may contribute to epithelial barrier alteration that has a pivotal role in the pathogenesis of IBD (9).

ISEMFs are an important source of MMP-2; however, there are few known regulation mechanisms of the production and activity of this enzyme in ISEMFs of CD patients. Previously, we have demonstrated in intestinal mucosa and ISEMFs of CD patients the presence of an increased oxidative state that was more remarkable in ill mucosa and in ISEMFs isolated from ill colonic mucosa of CD patients as compared to ISEMFs isolated from healthy mucosa [15, 16]. It has been demonstrated that the effect of oxidative stress on the MMP-2 expression, and activity is cell-type dependent and tissue specific [17]. Considering these previous data, the aim of this study was to demonstrate a relationship between MMP-2 activity and secretion and change in the glutathione/oxidized glutathione ratio (GSH/GSSG ratio), in CD patient ISEMFs stimulated or not with TNFα. Indeed, TNFα is a largely produced cytokine in CD patients [18], and it is involved on MMP-2 regulation in serum and intestine of these patients [19]. For this purpose, we have determined total and active MMP-2 in ISEMFs, isolated from mucosa of CD patients and control group, in which the intracellular redox state was modulated through buthionine sulfoximine (BSO) or N-acetylcysteine (NAC), inhibitor and precursor of glutathione (GSH) synthesis, respectively. The results were also confirmed in CCD-18Co cells (18Co), a myofibroblast cell line derived from human colonic mucosa exhibiting many proprieties of ISEMFs [20].

Materials and methods

Patients

Surgical specimens were taken from macroscopically and microscopically inflamed and unaffected colonic mucosa of four patients affected by active CD (mean age, 33 years; range, 20–55). The diagnosis of CD was ascertained according to the usual clinical criteria [21], and the site and extent of the disease were confirmed by endoscopic, histology and enteroclysis. The primary site involved was ileocolonic in all patients which were also in active phase of disease as documented by the Crohn’s disease activity index (ranging from 220–400). Patients with a score below 150 are considered to be in clinical remission, and scores above 450 reflect severe CD [20]. Moreover, the patients were treated with drugs prevalently used in CD pathology as mesalazine and steroids, but none of them had been treated with anti-TNFα therapies. Mucosal samples were also collected from colonic areas of four patients undergoing colectomy for colon cancer (mean age, 46 years; range, 36–60) used as control group. Steroid treatment was suspended at least 1 month earlier of surgery. All patients who participated in this study were recruited after their informed consent.

Cell cultures, treatments and stimulations

Primary cultures of ISEMFs were isolated from healthy and ill colonic mucosa of CD patients (HCD-ISEMFs and ICD-ISEMFs, respectively) and from mucosa of control group (C-ISEMFs) according the methods previously described by Mahida [22] and were grown to at least passage 4 before they were used in stimulation experiments. ISEMFs were
characterized by immunocytochemical staining, as previously described [23]. 18Co cells (normal human colon myofibroblasts) were obtained from American Type Culture Collection (Manassas, VA, USA) and were used in our experiments with population doubling level (PDL) 24–36 given that the line begins to senescce at about PDL=42. All cells were cultured at 37 °C in a 5 % CO2 atmosphere in minimum essential medium with 2 mM glutamine and 1.5 g/l sodium bicarbonate, 0.1 mM non-essential amino acids, 1 mM sodium pyruvate and 10 % foetal bovine serum. Culture media were supplemented with 72 mg/l penicillin and 100 mg/ml streptomycin.

ISEMFs were seeded in 12-well plates, serum starved at confluence for 48 h and subsequently stimulated for 24 h with 1 ng/ml TNFα (Sigma), at the same concentration previously used to stimulate these cells [16]. Forty eight-hour-starved C
ISEMFs were also stimulated after 25 μM BSO treatment performed during the last 16 h of starvation. Other stimulation experiments were performed in all human ISEMF starved for 48 h in the presence or not of 20 mM NAC added during the last 24 h. Each experiment performed on one cell line was repeated in triplicate. Altogether, the colonic intestine cell lines used were 12: four obtained from intestine of four controls, eight from ill and healthy intestine of four CD patients.

18Co cells, seeded in 12-well plates, were serum starved at confluence for 72 h and treated or not during the last 16 h or the last 24 h with 25 μM BSO (named BSO) or 20 mM NAC (named NAC), respectively. Other studies were performed in 48-h-starved cells treated during the last 16 h with 25 μM BSO and to which 20 mM NAC was added for other 24 h after removal or not of BSO; these cells were named NAC−BSO and NAC+BSO, respectively. Subsequently, after these all treatments, the cells were stimulated or not for other 24 h with 1 ng/ml TNFα. BSO, NAC and TNFα concentrations are those used previously to modulate intracellular redox state and which do not reduce viability according to trypan blue exclusion test [16].

Additional experiments were performed in serum-starved cells for 48 h in the presence or not of 25 μM BSO for the last 16 h or 20 mM NAC for the last 24 h of starvation and subsequently treated for 24 h with inhibitors of mitogen-activated protein kinases (MAPKs) and in particular with 2 μM SB203580 (p38 MAPK inhibitor) or 5 μM U0126 (extracellular signal-regulated kinases (ERK1/2) inhibitor) or 10 μM SP 600125 (c-Jun N-terminal kinase (JNK) (Calbiochem, La Jolla, CA, USA). These inhibitor concentrations used are those that induced the maximum inhibition without interfering with cellular viability.

GSH/GSSG ratio assay

GSH/GSSG ratio was obtained by cellular GSH and GSSG levels measured in confluent ISEMFs and 18Co seeded in 6-well plates, treated as reported above and collected in 0.2 ml of 5 % (v/v) aqueous HClO4 plus 10 μl of 1 mM γ-glutamyl-glutamate (internal standard). Cells were sonicated twice for 5 s, and GSH and GSSG were measured in cell extracts by high-performance liquid chromatography (HPLC) methods as previously reported [24].

MMP-2 activity assay

For quantification of active and total (pro and active) MMP-2, the supernatants of ISEMFs and 18Co cells, the high-sensitivity MMP-2 Activity Biotrak Assay System kit (GE Healthcare) was used according manufacturer’s instructions. This assay is performed in microtubes wells precoated with anti-MMP-2 antibody that bound active MMP-2 able to activate a detection enzyme, which in turn activates a detectable chromogenic substrate. Total MMP-2 activity (endogenously active plus the proenzyme) is measured by the addition of α-aminophenylmercuric acetate, which artificially activates the inactive form of MMP-2. Total and active MMP-2 levels were expressed in ISEMFs as fold increase over the total and active MMP-2 levels measured in untreated and unstimulated C
ISEMFs. Total and active MMP-2 levels were expressed in 18Co as fold increase over the total and active MMP-2 levels measured in untreated and unstimulated 18Co.

SDS-PAGE zymography

The effect of thiol compounds on the activity of secreted MMP-2 has been evaluated by gelatine zymography of untreated 18Co medium. Aliquots of MMP-2 containing medium of untreated and unstimulated 18Co cells underwent electrophoresis on 8 % polyacrilamide gels containing gelatine (1 mg/ml). Samples were mixed (10:1 v/v) with a sample buffer consisting of 50 mM Tris–HCl pH6.8, 2 % SDS, 20 % glycerol and 0.05 % bromophenol blue. After electrophoresis, the gels were then soaked in 2.5 % Triton X-100 (Sigma) on a shaker for 1 h at room temperature, then cut in strips and incubated overnight at 37 °C in the activation buffer (50 mM Tris–HCl pH7.5, 5 mM CaCl2, 200 Mm NaCl) at room temperature containing 20 mM NAC or 25 μM BSO. At the end of the incubation, the gels were stained with Coomassie brilliant blue R-250 (Sigma Aldrich, Italy) and destained with 30 % methanol and 10 % acetic acid. The gels were scanned by Chemo-Doc (Bio-Rad), utilizing the Quantity One program (Bio-Rad).

Western blotting

Analysis of phosphorylation of JNK was performed in ISEMFs and 18Co cells treated or not with BSO or NAC. Cells were lysed in ice-cold lysate buffer (50 mM Tris/HCl pH 7.5, 1 % Triton X100, 150 mM NaCl, 100 mM NaF, 2 mM EGTA, phosphatase and protease inhibitor cocktail, Sigma) and, after 15 min on ice, were centrifuged at 11,600×g for
10 min. Protein concentrations were determined by the bicinchoninic acid solution protein reagent assay (Pierce) [25] using bovine serum albumine as standard (Sigma). Equal amounts of total proteins (20–25 mg) were loaded in each line and were subjected to SDS/PAGE on 10 % (w/v) gel and electrotransferred to PVDF membrane (GE Healthcare) that was probed with specific antibody anti-JNK (cell signalling). Subsequently, membranes were stripped by incubation for 30 min at 50 °C in buffer containing 62.5 mM Tris/HCl, pH 6.7, 100 mM 2-mercaptoethanol, 2 % SDS and, after extensive washing, the membranes were reprobed with and anti-actin (cell signalling) to normalize and to perform a densitometric analysis. Secondary antibodies conjugated to horseradish peroxidase were used to detect antigen–antibody complexes with a chemiluminescence reagent kit (GE Healthcare). Chemidoc-Quantity-One software (Biorad Laboratories) was used to perform quantitative analyses, and values of the bands were expressed as percentage variations relative to values of unstimulated and untreated cells.

Statistical analysis

All experiments were carried out three or more times. Data are expressed as the mean±SEM, and statistical significance of the differences was determined using Student’s t test. \( P \leq 0.05 \) was considered statistically significant.

Ethical consideration

All patients who have participated in this study had to have undergone an operation, and they were recruited after their informed consent. We have required only this because the surgeon should have anyhow resected the surgical samples that we have used for our experiments.

Results

MMP-2 secretion and activation in ISEMFs

Figure 1a shows the data obtained by the analysis of MMP-2 secretion (total) and activation in the culture medium of ISEMFs stimulated or not for 24 h with 1 ng/ml TNF\( \alpha \). A significant enhanced secretion and activation of MMP-2 were measured in untreated and not TNF\( \alpha \) stimulated CD-ISEMFs as compared to C-ISEMFs in the same conditions. Subsequently, TNF\( \alpha \) stimulation induced a significant increase in both MMP-2 production and activity in all the untreated cells, and this effect was higher in CD-ISEMFs (Fig. 1a). Moreover, the greatest increase was measured in ICD-ISEMFs stimulation or not with TNF\( \alpha \) in comparison with HCD-ISEMFs.

To identify a relationship between the variations obtained in MMP-2 secretion and activity and the different oxidative status previously determined in ISEMFs [16], MMP-2 values were measured in ISEMFs, in which GSH levels and GSH/GSSG ratio were modulated by treatment with 25 \( \mu \)M
BSO or 20 mM NAC [20]. Table 1 shows that GSH/GSSG ratio decreased in BSO-treated C-ISEMFs, as compared to untreated cells, and this value was similar to that detected in CD-ISEMFs. On the contrary, NAC treatment increased GSH/GSSG ratio in all the ISEMF groups, in comparison with the respective untreated cells, and restored in HCD-ISEMFs, the ratio to the values measured in C-ISEMF, whereas this did not occur in ICD-ISEMFs (Table 1).

Figure 1b shows a significant increase in total MMP-2, as compared to untreated cells, in BSO-treated C-ISEMFs, stimulated or not with TNFα. On the contrary, NAC treatment significantly reduced MMP-2 secretion in all ISEMFs groups, stimulated or not with TNFα, as compared to the respective untreated cells. In particular, in HCD-ISEMFs, stimulated or not with TNFα, NAC treatment restored the values of MMP-2 secretion to those detected in untreated C-ISEMFs; whereas in ICD-ISEMFs, the total MMP-2 remained always higher than that measured in the same condition in C-ISEMF even if, in the presence of NAC, a significant decrease, as compared to the respective untreated cells, was registered. These data suggest a direct relationship between the increase of total MMP-2 and that of intracellular oxidative state. This is evident considering the changes of GSH/GSSG ratio obtained in the various experimental conditions (Table 1). Moreover, MMP-2 activity increased significantly in BSO-treated C-ISEMFs stimulated or not with TNFα, as compared with the respective untreated C-ISEMFs (Fig. 1c). NAC treatment decreased similarly MMP-2 activity in all the ISEMF groups stimulated or not with TNFα, differently to that observed for MMP-2 secretion and activation in 18Co cells treated or not with BSO or NAC.

To validate the findings obtained in ISEMFs, the relation between MMP-2 secretion and activation and GSH/GSSG ratio was investigated also in 18Co cells treated or not with BSO or NAC. As reported previously [12] in 18Co cells, BSO decreased and NAC increased GSH/GSSG ratio (Fig. 2). This ratio was restored to the value measured in untreated cells when NAC was added to cells pretreated with BSO (NAC+BSO) or after the removal of BSO (NAC–BSO) (Fig. 2). Moreover, the active MMP-2 values detected in NAC+BSO- and NAC+BSO-treated cells, stimulated or not with TNFα, MMP-2 secretion was restored to the values measured in the respective untreated cells (Fig. 3a) according to GSH/GSSG ratio (Fig. 2). On the contrary, the activity of MMP-2 in NAC, NAC+BSO- and NAC–BSO-treated 18Co cells, stimulated or not with TNFα, was similarly lower than that detected in the respective untreated cells (Fig. 2b) independently of GSH/GSSG ratio (Fig. 2).

### Table 1: Effect of NAC and BSO on the intracellular GSH/GSSG ratio in ISEMFs

|                | GSH/GSSG ratio |
|----------------|----------------|
|                | C-ISEMFs       | HCD-ISEMFs     | ICD-ISEMFs     |
| --             | 9.00±0.75      | 6.70±0.40\(^a\) | 4.70±0.25\(^{a,b}\) |
| NAC            | 23.4±1.75\(^a\) | 13.0±1.00\(^b\) | 7.00±0.35\(^{a,b}\) |
| BSO            | 5.80±0.48\(^a\) | --             | --             |

Starved cells were treated with 25 μM BSO and/or 20 mM NAC as reported in “Materials and methods,” and GSH/GSSG ratio was determined by GSH and GSSG values detected by HPLC method. The data expressed as nmol/mg proteins are the mean±SEM of four experiments performed, each in triplicate, on four controls and four CD patients. Each experiment, repeated in triplicate, was performed on a cell line obtained from one control intestine or from ill or healthy intestine of one patient affected by CD.

\(^a\) p≤0.05 compared to the untreated C-ISEMFs

\(^b\) p≤0.05 compared to the respective untreated cells

\(^c\) p≤0.05 compared to HCD-ISEMFs

Fig. 2 Effect of NAC and BSO on the intracellular GSH/GSSG ratio in 18Co cells. Starved cells were treated or not with 25 μM BSO and/or 20 mM NAC as reported in “Materials and methods.” GSH/GSSG ratio values, obtained by GSH and GSSG levels measured by HPLC method, are the mean±SEM of six experiments repeated in triplicate. Single asterisk (*) p≤0.01 compared to the untreated cells. Section symbol ($) p≤0.05 compared to BSO treated cells.
was measured in gel cut in strips and incubated in the activation buffer containing 20 mM NAC or 25 μM BSO. Data, reported in Table 2, indicate that BSO was ineffective, while NAC reduced MMP-2 activity of about 70 %.

Role of MAPK inhibitors on total MMP-2 in 18Co cells and ISEMF cells

Mitogen-activated protein kinases (MAPKs) are redox-regulated proteins [26] involved in the inflammatory response in colonic subepithelial myofibroblasts processes [27] and in the cascades participating in MMPs activation and expression [28–30]. Previously, we demonstrated that GSH depletion by BSO-activated ERK1/2 and p38MAPK increasing their phosphorylation in 18Co cells and in C-ISEMFs and that an increased activation of MAPKs occurred in HCD-ISEMFs and ICD-ISEMFs [16]. Therefore, we examined MMP-2 secretion in 18Co cells pre-incubated with specific inhibitors of MAPKs, U0126 for ERK1/2 [31], SB203580 for p38 MAPK [32] and SP600125 for JNK [33]. Figure 4a shows that in untreated 18Co cells, only SP600125 significantly decreased the MMP-2 secretion; on the contrary, in BSO-treated cells, MMP-2 secretion was inhibited by the three MAPKs inhibitors even if JNK inhibitor induced the major decrease in total MMP-2. No inhibitor affected MMP-2 secretion in NAC-treated 18Co cells (Fig.4a). Moreover, similar values were measured in untreated or BSO- or NAC-treated 18Co cells pre-incubated with SP600125 and were very similar among themselves (Fig. 4). Figure 4b shows that, in the three groups of ISEMFs, MMP-2 secretion was significantly inhibited only by SP600125.

Effect of BSO or NAC on the phosphorylation of JNK in 18Co cells

To investigate the activation of JNK in conditions of the different oxidative state, JNK phosphorylation in all ISEMF group was detected. Figure 5a shows that the phosphorylation of JNK increased significantly in CD-ISEMFs, as compared to C-ISEMFs, and in ICD-ISEMFs, this phosphorylation was higher than that measured in HCD-ISEMFs. An activation of JNK phosphorylation in BSO-treated C-ISEMFs occurred with respect to untreated C-ISEMFs. On the contrary, JNK phosphorylation was reduced in all ISEMF groups treated with NAC as compared to the respective untreated ISEMFs. It is evident in Fig. 5a that NAC restored JNK phosphorylation to C-ISEMFs values only in HCD-ISEMFs in according to GSH/GSSG ratio. These results have been also confirmed in 18Co cells treated or not with BSO or NAC (Fig. 5b). The phosphorylation of JNK increased significantly in BSO-treated cells in comparison with the untreated ones and decreased in NAC-treated 18Co cells. However, in NAC+BSO- and in NAC–BSO-treated cells, the phosphorylation levels were restored to the values of untreated cells. Overall, these results agree with the behaviour of total MMP-2 levels (Fig. 1) and indicate that JNK phosphorylation is inversely related to GSH/GSSG ratio (Table 1, Fig. 2).
Discussion

Intestinal fibroblasts and ISEMFs are the predominant source of MMP-2 in gut [34–36], and an increase in the number of myofibroblasts in the intestine of CD patients occurs [37]. These cells, secreting ECM and MMPs, are involved in changes of tissue architecture in this pathology. MMP-2 is commonly expressed by normal tissue participating in the control of collagen homeostasis in tissue [38, 39], and MMP-2 staining in normal and inflamed colon is localized in subepithelial and fibroblast/myofibroblast besides in mononuclear macrophage-like cells [40]. Data reported in literature show that activation and expression of MMP-2 increase in inflamed colonic mucosa if compared with non-inflamed colonic mucosa from the same CD patients [13, 14, 41] leading to epithelial damage, intestinal ulceration and/or fistula formation [14, 42, 43]. In fact, the increase in MMP-2 is most pronounced in colonic mucosa ulceration of IBD patients and in fistulae of CD patients [14, 40]. In this study, we showed that a significant increase in total and active MMP-2 in CD-ISEMFs occurs, as compared to C-ISEMFs. Moreover, in ICD-ISEMFs, these increases are more remarkable than those measured in HCD-ISEMFs in accordance with the increase in oxidative stress that characterizes CD-ISEMFs and in particular ICD-ISEMFs [16]. Therefore, we demonstrated, for the first time in these cells, a relation between the up-regulation of MMP-2 secretion and activation, stimulated or not by TNFα, and the decrease in GSH/GSSG ratio measured in CD-ISEMFs. The strong relationship between this ratio and MMP-2 secretion was highlighted in ISEMFs and 18Co cells by modulating GSH/GSSG ratio through NAC and/or BSO treatment. Moreover, it has been demonstrated in 18Co cells...
that NAC is able to remove BSO effect, restoring GSH/GSSG ratio and MMP-2 value to those of untreated cells. The dependence of the MMP-2 secretion from GSH/GSSG ratio is particularly evident in ISEMFS stimulated or not with TNFα and treated with NAC. In fact, in NAC-treated HCD-ISEMFs, the total MMP-2 levels and GSH/GSSG ratio are similar to those measured in untreated C-ISEMFs. On the contrary, in NAC-treated ICD-ISEMFs, MMP-2 secretion is lower than that of untreated C-ISEMF, in agreement with a higher value of GSH/GSSG ratio.

The increase in MMP-2 activity can be also related to GSH/GSSG ratio decrease in CD-ISEMFs untreated and stimulated or not with TNFα, as compared to the respective untreated C-ISEMFs. This datum agrees with the activation induced by oxidants on 72 kDa full-length MMP-2 through the disruption in the catalytic site of cysteine-Zn²⁺ interaction. Other data show also an induction of pro-MMP-2 activity due to S-glutathiolation of the cysteine in the propeptide domain, related to an increase of oxidative state. Effectively, in BSO-treated C-ISEMFs and 18Co cells, the decrease of GSH/GSSG is related to the increase of MMP-2 activity.

Differently to what was observed for MMP-2 secretion, NAC effect on MMP-2 activity in ISEMFS and 18Co cells is not related to the changes in GSH/GSSG ratio but to a direct effect of NAC on the proteinase, as demonstrated by gelatine zymography. In fact, NAC reduces MMP-2 activity in ISEMFSs and 18Co equally and independently from GSH/GSSG ratio. Moreover, NAC abolishes the stimulatory effect of TNFα, restoring MMP-2 values in ISEMFSs and 18Co cells to those of unstimulated and untreated C-ISEMFs and 18Co, respectively. The increased production of TNFα occurs during inflammation in the colon, and this stimulates the MMP-2 secretion. Our results suggest that TNFα in CD can amplify the inflammatory response also through the up-regulation of MMP-2 secretion and activation in ISEMFSs. In fact, an increased MMP-2 activity may play a role in the degradation of basement membrane which represents the support for endothelial and epithelial cells, increasing invasion of inflammatory cells. Moreover, in ISEMFSs, MMP-2 could be involved in the development of fibrosis, such as it occurs in the hepatic fibrosis. Therefore, for this, it should be very important to maintain MMP-2 values at physiological levels. Therefore, NAC, which reduces in ISEMFSs MMP-2 secretion by the increase of GSH/GSSG ratio and suppresses the activation of MMP-2 induced by TNFα, presents an important dual role in the normalization of MMP-2 values.

MAPK pathways can be activated by oxidative stress, and they play an important role in the regulation of MMP expression. Our data show that JNK is principally involved in the secretion of MMP-2 both in ISEMFSs and in 18Co cells, and JNK phosphorylation levels in both cell types are related to GSH/GSSG ratio. However, in BSO-treated 18Co cells, a low but significant reduction total MMP-2 occurs also in the presence of ERK1/2 and p38 MAPK inhibitors showing a partial involvement of these kinases on total MMP-2 levels. In fact, previously, we also observed in BSO-treated 18Co cells an increase in ERK1/2 and p38 MAPK phosphorylation. Differently to what verified for ERK1/2 and p38 MAPK, NAC decreases the JNK phosphorylation in 18Co cells and ISEMFSs; this is in accordance with the increase in GSH/GSSG ratio and the decrease in total MMP-2. NAC restores in 18Co cells JNK phosphorylation to the levels of untreated cells after and during BSO treatment, as such as restores GSH/GSSG ratio and total MMP-2. Differently to that occurs in HCD-ISEMFs, NAC treatment in ICD-ISEMFs does not restore JNK phosphorylation, GSH/GSSG ratio and MMP-2 levels to values of C-ISEMFs confirming the relationship among them. All together, these data show that NAC down-regulation effect on MMP-2 secretion is comparable to that observed with JNK inhibitor, suggesting that the increase of GSH/GSSG ratio induced by NAC reduces MMP-2 secretion inhibiting JNK. In fact, JNK can phosphorylate transcription factors such as JunB, JunD, c-fos, ATF2 and ATF3, which, along with c-Jun, make up the activator protein-1 transcription factor (AP-1). AP-1 modulates the expression of several stress-responsive genes and is an element found in most MMP promoters.

Conclusions

Our finding in CD-ISEMFs demonstrates (1) a relationship among MMP-2 secretion and activation, GSH/GSSG ratio and inflammatory state; (2) the involvement of ISEMFSs, stimulated or not with TNFα, in the increased activity and production of MMP-2 in intestinal mucosa of CD patients; (3) that NAC induced down-regulation of MMP-2 secretion through the increase of GSH/GSSG ratio, and this together with a direct action of NAC on the enzyme contribute to reduce MMP-2 activity; (4) that NAC may also suppress MMP-2 activation induced by TNFα and restore MMP-2 activity to physiological levels; and (5) the involvement of JNK pathway on redox regulation of MMP-2 secretion.

Moreover, this study suggests that compounds are able to modulate GSH components and to maintain GSH/GSSG ratio to physiological values can be useful to restore MMP-2 activity to normal values acting only on MMP-2 secretion and not directly on its activity. Indeed, the restore of normal MMP-2 level activity and/or expression can be important for help reduce in intestine of CD patients the dysfunction of epithelial barrier.

Acknowledgments This study was supported by a donation from the Ministero dell’Istruzione, dell’Università e della Ricerca and Fondazione Cassa di Risparmio di Firenze.
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Andoh A, Bamba S, Brittan M et al (2007) Role of intestinal subepithelial myofibroblasts in inflammation and regenerative response in the gut. Pharmacol Ther 114:94–106
2. Andoh A, Bamba S, Fujiyama Y et al (2005) Colonic subepithelial myofibroblasts in mucosal inflammation and repair: contribution of bone marrow-derived stem cells to the gut regenerative response. J Gastroenterol 40:1089–1099
3. Powell DW, Adegboyega PA, Di Mari JF, Mifflin RC (2005) Colonic subepithelial cells and their neighbors I. Role of intestinal myofibroblasts in development, repair, and cancer. Am J Physiol Gastrointest Liver Physiol 289:G2–G7
4. Ra HJ (2007) Parks WC Control of matrix metalloproteinase catalytic activity. Matrix Biol 26:587–596
5. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 87:1285–1342
6. Lemaitre V, D'Armiento J (2006) Matrix metalloproteinases in development and disease. Birth Defects Res C Embryo Today 78:1–10
7. Butler GS, Overall CM (2009) Updated biological roles for matrix metalloproteinases and new “intracellular” substrates revealed by degradomics. Biochemistry 48:10830–10845
8. Parks WC, Wilson CL, López-Boado YS (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4:617–629
9. Ravi A, Garg P, Sitaraman SV (2007) Matrix metalloproteinases in inflammatory bowel disease: boon or a bane? Inflamm Bowel Dis 13:97–107
10. Reimund JM, Wittersheim C, Dumont S et al (1996) Increased production of tumour necrosis factor-alpha interleukin-1 beta, and interleukin-6 by morphologically normal intestinal biopsies from patients with Crohn's disease. Gut 39:684–689
11. Naito Y, Yoshikawa T (2005) Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 26:379–396
12. McKaig BC, McWilliams D, Watson SA, McPhail JS, Bamba S, Andoh A, Brittan M et al (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355–1360
13. Gao Q, Meijer MJ, Rubben FJ et al (2005) Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 37:584–592
14. von Lampe B, Barthel B, Coupland SE et al (2000) Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 47:63–73
15. Iantomasi T, Marraccini P, Favilli F et al (1994) Glutathione metabolism in Crohn's disease. Biochem Med Metab Biol 53:87–91
16. Catarzi S, Favilli F, Romagnoli C et al (2011) Oxidative state and IL-6 production in intestinal myofibroblasts of Crohn's disease patients. Inflamm Bowel Dis 17:1674–1684
17. Vincenti MP, Brinkerhoff CE (2007) Signal transduction and cell-type specific regulation of matrix metalloproteinase gene expression: can MMPs be good for you? J Cell Physiol 213:355–364
18. Papadakis KA, Targan SR (2000) Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 119:1148–1157
19. Gao Q, Meijer MJ, Schlüter UG, van Hogezen RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW (2007) Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 13:693–702
20. Valentij TD, Popov V, Saada JI, Powell DW (1997) Phenotypic characterization of an intestinal subepithelial myofibroblast cell line. Am J Physiol 272:C1513–C1524
21. Best WR, Becktel JM, Singleton JW, Kern FJ (1976) Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439–444
22. Okuno T, Andoh A, Bamba S, Ando H, Schöffski O, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW (2007) Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm Bowel Dis 13:693–702
23. Di Sabatino A, Pender SL, Jackson CL et al (2007) Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133:137–149
24. Iantomasi T, Favilli F, De'lonnecchi D, Vincenzini M (1999) Increased glutathione synthesis associated with platelet-derived growth factor stimulation of NIH3T3 fibroblasts. Biochim Biophys Acta 1452:303–312
25. Smith PK, Kohr RI, Hermanson GT et al (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150:76–85
26. Matsuzawa A, Ichijo H (2008) Redox control of cell fate by MAP kinase: physiological roles of ASK1-MAP kinase pathway in stress signaling. Biochem Biophys Acta 1780:1325–1336
27. Hata K, Andoh A, Shimada M et al (2002) IL-17 stimulates inflammatory responses via NF-kappaB and MAP kinase pathways in human colonic myofibroblasts. Am J Physiol Gastrointestinal Liver Physiol 282:G1035–G1044
28. Lin CW, Hou WC, Shen SC et al (2008) Quercetin inhibition of tumor invasion via suppressing PKC delta/ERK/AP-1-dependent matrix metalloproteinase-9 activation in breast carcinoma cells. Carcinogenesis 29(9):1807–1815
29. Cohen M, Meissner A, Haenggeli L, Bischof P (2006) Involvement of MAPK pathway in TNF-alpha-induced MMP-9 expression in human trophoblastic cells. Mol Hum Reprod 12:225–232
30. Kajanne R, Miettinen P, Mehlem A et al (2007) EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 212:489–497
31. Hotokezaka H, Sakai E, Kanaoka K et al (2002) U0126 and PD98059, specific inhibitors of MEK, accelerate differentiation of RAW264.7 cells into osteoclast-like cells, J Biol Chem 277:47366–47372
32. Guo RX, Zhang M, Liu W et al (2009) NMDA receptors are involved in upstream of the spinal JNK activation in morphine antinociceptive tolerance. Neurosci Lett 467:95–99
33. Rossa C Jr, Liu M, Patil C, Kirkwood KL (2005) MKK3/6-p38 MAPK negatively regulates murine MMP-13 gene expression induced by IL-1beta and TNF-alpha in immortalized periodontal ligament fibroblasts. Matrix Biol 24:478–488
34. McKaig BC, McWilliams D, Watson SA, Mahida YR (2003) Expression and regulation of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinases by intestinal myofibroblasts in inflammatory bowel disease. Am J Pathol 162:1355–1360
35. Monteleone G, Caruso R, Fina D et al (2006) Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55:1774–1780
36. Okuno T, Andoh A, Bamba S et al (2002) Interleukin-1beta and tumor necrosis factor-alpha induce chemokine and matrix metalloproteinase gene expression in human colonic subepithelial myofibroblasts. Scand J Gastroenterol 37:317–324
37. Theiss AL, Simmons JG, Jobin C, Lund PK (2005) Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem 280:36099–36109
38. Matrisian LM (1994) Matrix metalloproteinase gene expression. Ann N Y Acad Sci 732:42–50
39. Agren MS (1994) Gelatinase activity during wound healing. Br J Dermatol 131:634–640
40. Kirkegaard T, Hansen A, Bruun E, Brynskov J (2004) Expression and localisation of matrix metalloproteinases and their natural inhibitors in fistulae of patients with Crohn's disease. Gut 53:701–709
41. Meijer MJ, Mieremet-Ooms MA, van der Zon AM et al (2007) Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis 39:733–739
42. Stallmach A, Chan CC, Ecker KW et al (2000) Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. Gut 47:415–422
43. Matsuno K, Adachi Y, Yamamoto H et al (2003) The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol 38:348–354
44. Svineng G, Ravuri C, Rikardsen O et al (2008) The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. Connect Tissue Res 49:197–202
45. Ye H, Cai PC, Zhou Q, Ma WL (2011) Transforming growth factor-β1 suppresses the up-regulation of matrix metalloproteinase-2 by lung fibroblasts in response to tumor necrosis factor-α. Wound Repair Regen 19:392–399
46. Galli A, Svegliati-Baroni G, Ceni E et al (2005) Oxidative stress stimulates proliferation and invasiveness of hepatic stellate cells via a MMP2-mediated mechanism. Hepatology 5:1074–1084
47. Alge-Priglinger CS, Kreutzer T, Obholzer K et al (2009) Oxidative stress-mediated induction of MMP-1 and MMP-3 in human RPE cells. Invest Ophthalmol Vis Sci 50:5495–5503
48. McCubrey JA, Lahair MM, Franklin RA (2006) Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid Redox Signal 8:1775–1789
49. Li L, Chen P, Ling Y et al (2011) Inhibitory effects of GL-V9 on the invasion of human breast carcinoma cells by downregulating the expression and activity of matrix metalloproteinase-2/9. Eur J Pharm Sci 43:393–399
50. Roy PK, Rashid F, Bragg J, Ibdah JA (2008) Role of the JNK signal transduction pathway in inflammatory bowel disease. World J Gastroenterol 14:200–202
51. Wu X, Li L (2012) Rosiglitazone suppresses lipopolysaccharide-induced matrix metalloproteinase-2 activity in rat aortic endothelial cells via Ras-MEK1/2 signaling. Int J Cardiol 158:54–58